Quick Facts: Therapeutic Domains

• Joint Conditions: Used for the symptomatic management of pain and inflammation associated with conditions affecting the joints and spine.
• Rheumatological Relief: Helps address symptoms related to rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
• Musculoskeletal Discomfort: Provides options for managing other painful inflammatory processes, such as general low back pain and soft tissue rheumatism.

---

Ацеклагин is an option for the symptomatic management of pain and inflammation. Its use is focused on addressing discomfort in various musculoskeletal and rheumatological conditions. Clinical experience suggests its suitability for helping patients manage the symptoms of chronic joint disorders.

Therapeutic domains include the management of pain and stiffness associated with rheumatoid arthritis and ankylosing spondylitis. It is also indicated for reducing discomfort and improving functional capacity in individuals with osteoarthritis.

Additional clinical applications include support for managing other painful inflammatory processes, such as low back pain, dental pain, and conditions affecting the soft tissues surrounding the joints. Ацеклагин may contribute to a reduction in inflammation, providing relief across a wide range of these common painful conditions.

Who Can and Cannot Use Aceclofenac

Official regulatory guidelines define specific populations for whom the use of Aceclofenac (Ацеклагин) is permitted, restricted, or strictly prohibited. Eligibility is based on age, pre-existing comorbidities, and physiological states, adhering to a framework of absolute exclusion and conditional allowance.

---

Contraindications and Non-Eligibility

Use is strictly contraindicated in patients with a known history of hypersensitivity to aceclofenac or any other NSAID, including aspirin. Absolute prohibitions also apply to individuals with severe hepatic or renal failure and those with active or history of recurrent peptic ulceration or haemorrhage.

Furthermore, the medicine is contraindicated in patients with established cardiovascular disease, such as congestive heart failure (NYHA II–IV), established ischaemic heart disease, or cerebrovascular disease.

---

Restricted and Conditional Use

Population/Condition	Regulatory Status
Pediatric Population (under 18)	Not recommended (due to insufficient clinical data).
Older Adults (Elderly)	Use requires the lowest effective dose for the shortest duration.
Third Trimester Pregnancy	Contraindicated.
Mild Organ Impairment	Use requires caution and close medical surveillance (e.g., mild to moderate hepatic impairment).

Use is also not recommended for women attempting to conceive or while breastfeeding.

Aceclofenac (Ацеклагин) interactions are classified by regulatory authorities based on resulting risks of organ toxicity, synergistic adverse effects, and altered drug exposure. This information is derived exclusively from official regulatory documents.

Contraindicated Combinations

Co-administration is strictly prohibited with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose acetylsalicylic acid (aspirin), due to a documented, substantially increased risk of gastrointestinal bleeding and ulceration. The medicine is also contraindicated for 8–12 days following mifepristone administration.

Clinically Significant Interaction Patterns

Interactions with certain medicinal products primarily result from pharmacodynamic risk or altered clearance.

Interacting Substance/Class	Official Interaction Description	Resulting Regulatory Note
Anticoagulants (e.g., Warfarin)	Increases the risk of serious haemorrhage (bleeding).	Requires close monitoring of coagulation status (INR/prothrombin time).
Lithium or Digoxin	Aceclofenac may increase the plasma concentrations of these agents.	Regulatory caution due to potential toxicity from reduced clearance.
Corticosteroids, SSRIs	Pharmacodynamic effects increase the risk of gastrointestinal bleeding.	Use must be closely managed due to additive risk.
Diuretics/Antihypertensives	May reduce the antihypertensive effect and increase the risk of acute renal failure.	Caution advised, particularly in the elderly or those with impaired renal function.
Ciclosporin or Tacrolimus	Officially increases the risk of nephrotoxicity (kidney damage).	Special caution advised.

Additionally, the regulatory profile notes that co-administration with alcohol may increase the risk of gastrointestinal bleeding.

How Ацеклагин Works

The mechanism of action for Ацеклагин (Aceclofenac) is focused on the interruption of key inflammatory signaling pathways, leading directly to predictable physiological adjustments at the tissue level.

---

Modulating Inflammatory Chemical Messengers

The drug acts by initiating reversible competitive inhibition of the Cyclooxygenase (COX) enzymes, targeting the inducible COX-2 isoform. This core action blocks the Arachidonic Acid Cascade, thereby reducing the synthesis of various inflammatory mediators, chiefly prostaglandins (PGs). This mechanism modifies the chemical signals that regulate the inflammatory response and is the first molecular step in the resulting physiological adjustment.

---

Dampening Peripheral Nociceptor Sensitization

The physiological reduction in prostaglandins directly affects the peripheral nociceptive system by decreasing the chemical signals that sensitize nerve endings. Prostaglandins typically cause peripheral nerve fibers to become hyper-responsive to mechanical or chemical stimuli. By reducing their synthesis, the mechanism promotes the desensitization of peripheral nociceptors, which modulates the activity of the nociceptive pathway and alters the impact of chemical mediators on nerve fibers.

---

Regulating Local Fluid Dynamics

The molecular suppression of prostaglandins also influences local vascular dynamics. PGs are potent chemicals that promote vasodilation and increased capillary permeability, leading to the leakage of fluid into the tissues. By engaging mechanisms that regulate prostaglandin activity, the drug modulates local vascular permeability, thereby limiting the accumulation of fluid in the targeted tissue.

How to Use Ацеклагин

This section describes the administration principles and dosage regimens for aceclofenac, the active substance in Ацеклагин.

General Administration Protocol

Aceclofenac is administered orally and is commonly available as a 100 mg film-coated tablet. For proper use, tablets must be swallowed whole with a quantity of liquid, such as a glass of water, and must not be crushed or chewed. The tablet should be taken preferably with or immediately after food.

Dosing and Frequency

The standard maximum recommended total daily dose for adults is 200 mg. This is typically administered as 100 mg twice daily, with one dose taken in the morning and the second in the evening.

Usage Principle	Instruction
Route of Administration	Oral (Swallowing whole)
Standard Daily Dose	Maximum 200 mg
Standard Frequency	Twice daily (100 mg morning, 100 mg evening)
Timing Relative to Food	Taken with or after food
Duration Principle	Use the lowest effective dose for the shortest duration necessary

Population-Specific Adjustments

Guidelines exist for specific patient groups regarding initial dosing. For patients with hepatic impairment, the starting daily dose should be reduced to 100 mg. While no dose modification is generally required for the elderly or those with mild renal impairment, the overall therapeutic strategy must adhere to the principle of using the lowest effective dose for the shortest duration.

Research Evidence / Overview of Studies for Ацеклагин

Evidence for Use in Chronic Joint Disorders

Research has examined aceclofenac (the active substance in Ацеклагин) in chronic conditions characterized by functional limitations and outcomes related to physical discomfort, evaluating its study in clinical settings focusing on patients with osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). Research explored how symptoms change over time in these patient populations.

The primary research structure includes numerous Randomized Controlled Trials (RCTs) and aggregated data from meta-analyses. Research examined outcomes reflecting daily functioning or activity level (such as the WOMAC Index) alongside patient-reported outcomes describing perceived discomfort. Findings describe how patient-reported outcomes evolved during the short- to intermediate-term follow-up periods. Research describes that the outcomes measured during the study period data show patterns related to those observed in trials involving other active comparator medicines.

---

Research on General Musculoskeletal Pain

Research explored the substance aceclofenac in studies that included patients with chronic low back pain (CLBP) and other conditions involving fluctuating or unstable symptoms. Studies monitored how symptoms evolved in the observed populations with conditions where symptoms may vary in intensity. Research examined short-term symptom changes using clinical trials, some of which focused on comparing different oral formulations of the medicine.

Studies explored the outcomes related to physical discomfort and functional disability related to the spine (e.g., the Oswestry Disability Index). Findings describe patterns where symptomatic pain scores and functional disability metrics were assessed over defined, short time intervals. This research describes short-term changes during episodes where symptoms become more noticeable.

---

Key Limitations and Areas of Research Uncertainty

Research describes several limitations regarding the current evidence base. The majority of data available from the core randomized clinical trials spans a short-term follow-up duration (typically between four and twelve weeks). Long-term effects are not fully established based on the existing structure of randomized evidence, and certainty remains low regarding the durability of observed symptomatic patterns across extended periods. Furthermore, scientific publications note that methodological heterogeneity and modest sample sizes among some individual studies contribute to research uncertainty.

Key Studies & References

1. A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders

Common questions about Ацеклагин (FAQ)

Q: What is the difference between Ацеклагин and other common medicines for joint discomfort?

Official information describes aceclofenac, the active substance in Ацеклагин, as having a favorable gastrointestinal tolerability profile compared to some older, non-selective NSAIDs. This comparative feature, related to potential effects on the digestive system, is one point of distinction described in clinical reviews.

Q: Can Ацеклагин be crushed or split if it's hard to swallow?

Official administration protocol states that the tablets must be swallowed whole with liquid and should not be crushed, split, or chewed. This instruction ensures the medicine is absorbed correctly as it was designed.

Q: How long does it usually take to notice an effect from Ацеклагин?

Pharmacokinetic data from studies describes how the medicine is absorbed in the body. Peak plasma concentration, which is when the highest concentration of the drug is measured in the bloodstream, is generally reached about 1.25 to 3 hours after the tablet is swallowed.

Q: How quickly does Ацеклагин leave the body?

The time described for the concentration of aceclofenac to reduce by half in the bloodstream, known as the elimination half-life, is approximately 4 hours.

Q: Can Ацеклагин affect fertility?

Official labeling notes that the use of aceclofenac, like other medicines in its class, may impair female fertility. For this reason, its use is generally not recommended for women who are actively attempting to conceive.

Q: Are there any known interactions between Ацеклагин and common heart medications?

Regulatory documents describe interactions with several classes of heart-related medicines. These include diuretics, antihypertensives (used for high blood pressure), and certain cardiac glycosides like digoxin. These interactions could potentially affect the function of those heart medicines or change the concentration of the drugs in the body.

Q: Why is Ацеклагин sometimes prescribed with a stomach protector medicine?

As an NSAID, regulatory warnings state that Ацеклагин carries a risk of serious side effects involving the stomach and intestines, such as bleeding or ulceration. The co-administration of protective agents is a common strategy documented in literature to manage this potential gastrointestinal risk for at-risk patients.

Q: Is it generally safe to drive or operate machinery after taking Ацеклагин?

Regulatory information advises that individuals who experience undesirable effects such as dizziness, drowsiness, vertigo, or visual disturbances should refrain from driving or operating machines. A person’s ability to perform these tasks may be impaired by the medicine's effects.

Q: Does Ацеклагин have different names in other countries?

Yes, the active substance, aceclofenac, is marketed internationally under many different brand names beyond Ацеклагин, depending on the country and the specific pharmaceutical company.

Q: Is Ацеклагин safe to use for a long time?

Official research evidence notes that the majority of controlled clinical trial data is short-term (typically 4–12 weeks), and the long-term symptomatic patterns of use are not fully established based on this evidence structure. Regulatory guidelines emphasize using the lowest effective dose for the shortest duration necessary.

Q: Can Ацеклагин make you feel dizzy or drowsy?

Official reports of undesirable effects list dizziness as a common side effect of the medicine. Drowsiness (somnolence) is also listed as an occasional, though less frequently reported, side effect.

Q: Is there any research looking at the use of Ацеклагин for muscle pain?

Clinical research has specifically explored the substance in studies for painful conditions including chronic low back pain (CLBP), in addition to the major inflammatory joint disorders. This falls under the general scope of musculoskeletal pain management.

Q: Is Ацеклагин available without a prescription?

In most regions, this medicine is classified as a Prescription-Only Medicine. This means that a prescription from an authorized healthcare professional is required to obtain it.

Q: Can Ацеклагин affect my sleep?

Official side effect lists include central nervous system (CNS) effects such as dizziness and drowsiness. Reports of effects like depression and vertigo are also noted, which may indirectly influence a person’s quality of sleep.

Q: Are there generic versions of Ацеклагин?

Yes. Since the original patents for the active substance, aceclofenac, have expired, regulatory bodies in different regions have authorized the marketing of multiple generic versions of the medicine under various brand names.

Q: Are the side effects of Ацеклагин the same for everyone?

No. Regulatory documents classify side effects by their frequency (e.g., Common, Uncommon, Rare), which indicates that the occurrence of these effects varies across the population. Not everyone experiences the same effects, and some people may not experience any.

Q: Does Ацеклагин work for all kinds of pain?

The official indications limit the use of the drug to the symptomatic relief of pain and inflammation in specific conditions: osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is not indicated for the management of all types of pain.

Q: What is the difference between the immediate-release and extended-release forms of Ацеклагин?

Modified-release or sustained-release formulations are designed to control the rate of release of the medicine into the body. This is done to maintain sustained therapeutic levels over a longer period, supporting a less frequent dosing schedule compared to formulations that release the medicine immediately.

Q: What are the signs of a serious side effect from Ацеклагин?

Official warnings specify that you should seek immediate medical attention for serious signs. These include black, tarry stools, vomiting blood, severe abdominal pain, or the first sign of a skin rash or mucosal lesions (such as in the mouth or eyes), as these may indicate severe internal or external reactions.

Q: Does Ацеклагин affect the liver?

Yes, regulatory documents note that changes in the liver can occur. Official side effect lists include reports of elevated liver enzymes (which are detected through blood tests), and severe hepatic (liver) failure is listed as a contraindication for using the drug. Additionally, hepatitis is listed as a very rare reported side effect.

Q: Why do doctors prefer Ацеклагин over other similar drugs in certain cases?

Official reviews note that aceclofenac is clinically recognized for its favorable gastrointestinal tolerability compared to some older NSAIDs in its class. This characteristic may be a factor described in the literature when considering the needs of certain patient profiles.

Q: Does Ацеклагин change how the immune system works?

Official warnings state that NSAIDs like aceclofenac may be associated with an increased risk of conditions like aseptic meningitis in patients who have pre-existing autoimmune disorders, such as Systemic Lupus Erythematosus. This condition involves changes in the immune system.

Q: Can Ацеклагин be used to reduce fever?

While the drug belongs to the NSAID class, which is associated with antipyretic (fever-reducing) effects, the official therapeutic indications for the drug do not specifically list fever reduction as an approved use.

How to Store and Dispose of Aceclagin (Aceclofenac)

Official regulatory guidelines define specific conditions for the storage and disposal of Aceclagin tablets to ensure product stability and safety.

Storage Requirements

Aceclagin must be stored at a temperature below 25°C; some regional labeling permits storage below 30°C. The medicine must be kept in its original container and protected from both light and moisture. It is prohibited to refrigerate or freeze the tablets. For safety, the product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Aceclagin must be disposed of in accordance with local requirements. The medicine should not be disposed of in household waste or flushed down the toilet, as environmental restrictions prohibit its release into the water system.